Overview
Uncontrolled asthma is characterized by persistent symptoms despite treatment, frequent exacerbations, and impaired lung function, necessitating aggressive management to prevent severe complications 1.Diagnosis
Persistent symptoms (wheezing, shortness of breath, chest tightness, cough) despite treatment 1.
Frequent use of short-acting beta-agonists (SABA) for symptom relief 1.
Evidence of airflow obstruction on spirometry (FEV1/FVC ratio < 0.70) 1.
Elevated fractional exhaled nitric oxide (FeNO) levels (indicative of eosinophilic inflammation) 1.
Increased sputum eosinophil counts (if sputum induction is performed) 1.Management
First-line treatments:
- Inhaled corticosteroids (ICS) at high doses (e.g., fluticasone 1000 mcg/day) 1.
- Addition of long-acting beta-agonists (LABA) to ICS (e.g., salmeterol/fluticasone combination) 1.
Adjunctive treatments:
- Leukotriene receptor antagonists (e.g., montelukast) for additional control 1.
- Short-term use of oral corticosteroids for acute exacerbations 1.
- Consider anti-IgE therapy (omalizumab) in severe cases with persistent eosinophilic inflammation 1.Special Populations
Pregnancy: Close monitoring and individualized treatment plans with ICS as first-line, avoiding systemic corticosteroids unless absolutely necessary 1.
Pediatrics: Early intervention with high-dose ICS and LABA, tailored to age-appropriate formulations 1.
Elderly: Focus on minimizing side effects while ensuring adequate control; consider step-up therapy cautiously 1.
Comorbidities: Tailored management considering coexisting conditions; adjust asthma therapy to avoid drug interactions and manage symptoms synergistically 1.Key Recommendations
Initiate high-dose inhaled corticosteroids and add long-acting beta-agonists for uncontrolled asthma to achieve better symptom control and reduce exacerbations (Evidence: Strong 1).
Consider short-term oral corticosteroids for acute exacerbations to rapidly improve lung function and reduce symptoms (Evidence: Moderate 1).
Evaluate and manage eosinophilic inflammation with options like leukotriene receptor antagonists or anti-IgE therapy in severe cases (Evidence: Moderate 1).References
1 Stern SA, Wang X, Mertz M, Chowanski ZP, Remick DG, Kim HM et al.. Under-resuscitation of near-lethal uncontrolled hemorrhage: effects on mortality and end-organ function at 72 hours. Shock (Augusta, Ga.) 2001. link